Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience

被引:29
作者
Delia, P [1 ]
Sansotta, G [1 ]
Donato, V [1 ]
Messina, G [1 ]
Frosina, P [1 ]
Pergolizzi, S [1 ]
De Renzis, C [1 ]
机构
[1] Univ Messina, Azienda Osped G Martino, Div Radioterapia Oncol, Ist Sci Radiol,Oncol Radiotherapy Unit, I-98124 Messina, Italy
关键词
diarrhoea; probiotics; radiotherapy;
D O I
10.1016/S1590-8658(02)80173-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Diarrhoea is a severe side-effect of radiotherapy on the pelvic area. It is due to acute enteric damage. We aimed at determining the ability of a highly concentrated freeze-dried living bacteria compound (VSL/3) to reduce these side-effects in 190 patients receiving radio therapy on the pelvic area. A total of 95 patients received radiotherapy alone and 95 were also administered VSL/3 bags, at doses of one bag three times a day beginning on the first day of the radiotherapy treatment. The same diet was indicated for both groups. All patients were Irradiated for 6 to 7 weeks, with Linac X-6 MV or 15 MV through a box multiportal technique with the lower limit of the fields below the obturator foramina, upper limit at L5-S1, lateral limit 1.5 cm beyond the innominate hip. The total radiated dose ranged from 60 to 70 Gy for a dally dose of 180 cGy Gastroenteric toxicity was rated in WHO degrees. Two patients receiving radiotherapy alone had to discontinue the treatment due to acute enteritis. Toxicity was found In 52 (50.6%) patients with radiotherapy alone vs 36 (30.5%) patients receiving VSL/3. None of them had to discontinue radiotherapy. Toxicity of degrees 3 or 4 was found in 28 patients receiving radiotherapy alone vs 7 with VSL/3. These preliminary data suggest the effectiveness of VSL/3 in preventing the occurrence of diarrhoea in patients submitted to radiotherapy, with a direct and indirect improvement of their quality of life and a good tolerance.
引用
收藏
页码:S84 / S86
页数:3
相关论文
共 10 条
[1]  
AMICHETTI M, 1997, IL TRATTAMENTO RAD C, P125
[2]  
CAPIRCI C, 1998, RECIDIVE PELVICHE NE, P100
[3]  
CAPIRCI C, 1993, INT C RAD ONC, V1, P405
[4]  
DESIMONE C, 1999, G GASTROENTEROL S1, V4, P4
[5]   PROBIOTICS IN HUMAN MEDICINE [J].
FULLER, R .
GUT, 1991, 32 (04) :439-442
[6]  
INTVELD JHJ, 1993, PROBIOTICS PATHOGENI, P11
[7]  
Martinez-Val J. M., 1992, Proceedings of the 1992 9th International Conference on High-Power Particle Beams, P1001
[8]  
MOSS WT, 1985, RADIOTERAPIA ONCOLOG
[9]  
PALMARA D, 1992, PATOLOGIA IATROGENA, P85
[10]   GUT FLORA IN NORMAL AND DISORDERED STATES [J].
SALMINEN, S ;
ISOLAURI, E ;
ONNELA, T .
CHEMOTHERAPY, 1995, 41 :5-15